On November 25, Gelonghui reported that Huayu Pharmaceutical (688553.SH) announced that its wholly-owned subsidiary Seacross Pharmaceuticals Ltd. recently received the marketing licenses for its products, injectable voriconazole and fluvestrant injection, issued by the United Kingdom's Medicines and Healthcare products Regulatory Agency.

Injectable voriconazole is a broad-spectrum triazole antifungal drug, primarily used to treat invasive aspergillosis; to treat severe invasive infections caused by Candida that are resistant to fluconazole (including Candida krusei); to treat severe fungal infections caused by the genera Nocardia and Fusarium; and to treat progressive, potentially life-threatening infections in immunocompromised patients. It also prevents invasive fungal infections in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT).

Fluvestrant injection is an anti-cancer drug used for postmenopausal (including natural and artificial menopause) estrogen receptor-positive locally advanced or metastatic breast cancer that recurs after or during anti-estrogen adjuvant therapy, or progresses during anti-estrogen treatment; it is suitable for local advanced or metastatic breast cancer, hormone receptor (HR) positive, and human epidermal growth factor receptor 2 (HER2) negative when used in combination with abemaciclib, specifically for patients who have experienced disease progression after prior endocrine therapy.

The marketing licenses obtained in the United Kingdom for injectable voriconazole and fluvestrant injection developed by the company will help enrich the company’s product pipeline in the international market, enhance the brand image in the market, and continuously expand the breadth and depth of international business, further solidifying the foundation for sustainable development in international markets.